Population
Children with Kawasaki disease (most commonly aged 6 months to 5 years)
Design
Review
Authors
Loading...
Supports guideline-directed Kawasaki therapy in the UK; leaves open optimal dosing, resistance predictors, and long-term outcomes.
Kawasaki disease is a major cause of acquired coronary abnormalities in children, and treatment with immunoglobulin and aspirin significantly reduces cardiac complications.
L Wood (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: